Welcome to our dedicated page for Axcella Health news (Ticker: AXLA), a resource for investors and traders seeking the latest updates and insights on Axcella Health stock.
Axcella Health Inc. (NASDAQ: AXLA) is an innovative biotechnology company dedicated to pioneering new therapeutic solutions through its proprietary Defined Amino Acid Compositions (DAACs™). These compositions harness the essential signaling capabilities of amino acids to address and rectify dysregulated pathways, offering safer treatments for patients with complex diseases.
With the groundbreaking Axcelerator™ platform, Axcella is revolutionizing traditional drug discovery and development. This platform allows for the generation of comprehensive patient data in less than a year from the selection of an indication, significantly accelerating the process of bringing new therapies to market. The Axcelerator™ platform has already produced a robust pipeline of clinical programs targeting a wide range of conditions, including liver diseases, metabolic disorders, central nervous system (CNS) diseases, and orphan diseases.
Recent achievements by Axcella include notable advancements in its clinical programs. The company has made significant strides in developing treatments for liver diseases and metabolic disorders, leveraging its DAAC-based therapies to provide innovative solutions where traditional treatments fall short.
As a forward-thinking entity in the biotech space, Axcella has forged key partnerships to enhance its research and development capabilities. These collaborations are pivotal in supporting the company’s mission to deliver effective and safe therapeutic options for patients with complex and underserved medical needs.
Financially, Axcella continues to focus on sustainable growth and development. The company is actively engaged in securing funding to support its research initiatives and clinical trials. With a commitment to transparency and progress, Axcella regularly updates its investors and stakeholders on its financial condition, strategic goals, and operational milestones.
In summary, Axcella Health Inc. stands at the forefront of biotechnological innovation, offering cutting-edge solutions through DAAC therapeutics and the Axcelerator™ platform. The company’s dedication to improving patient outcomes and its proactive approach to drug development position it as a significant player in the biotech industry.
Axcella Therapeutics (AXLA) has initiated patient screening for a Phase 2a clinical trial of its oral candidate AXA1125, aimed at treating Long COVID, particularly fatigue and muscle weakness. The trial, conducted in collaboration with Oxford University, will enroll approximately 40 patients in the UK, with top-line data expected by mid-2022. AXA1125 is believed to enhance mitochondrial function, offering hope for those suffering from debilitating Long COVID symptoms. The primary endpoint is phosphocreatine recovery time, with secondary endpoints including lactate levels and fatigue scores.
Axcella Therapeutics (Nasdaq: AXLA) has announced the promotion of Dr. Margaret Koziel to Chief Medical Officer, effective immediately. Dr. Koziel, who joined Axcella in 2019, has led multiple successful clinical studies and will oversee clinical development and regulatory affairs moving forward. Axcella is advancing its lead candidates, AXA1125 and AXA1665, through three Phase 2 trials aimed at treating complex diseases including Long COVID, non-alcoholic steatohepatitis (NASH), and overt hepatic encephalopathy (OHE). CEO Bill Hinshaw commended her contributions as pivotal for the company's growth.
Axcella Therapeutics (Nasdaq: AXLA) announced its participation in the Piper Sandler 33rd Annual Healthcare Conference. A fireside chat from the event will be available on www.axcellatx.com starting Monday, November 22, at 10 a.m. ET, and will be archived for 90 days. Axcella focuses on innovative treatments for complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates for conditions like overt hepatic encephalopathy and Long COVID.
Axcella Therapeutics (Nasdaq: AXLA) announced its Q3 2021 financial results, reporting a net loss of $15.6 million, or $0.41 per share, compared to $12.4 million the previous year. The company highlighted the initiation of clinical trials for AXA1125, targeting Long COVID and liver diseases. Axcella has $66.1 million in cash, sufficient to fund operations until Q3 2022. R&D expenses rose to $10.1 million due to increased clinical activities. The departure of CFO Laurent Chardonnet was also announced, while ongoing trials are set to yield critical data in the coming months.
Axcella Therapeutics (Nasdaq: AXLA) announced two upcoming poster presentations at The Liver Meeting® 2021, taking place virtually from November 12-15, 2021. These presentations will detail data on AXA1125 for nonalcoholic steatohepatitis (NASH) and AXA1665 for overt hepatic encephalopathy (OHE). Abstracts include:
- Abstract 1855: Predictive metabolic profile changes in NAFLD.
- Abstract 259: Dose-dependent metabolic profile alterations in healthy subjects.
Attendees can visit Axcella's virtual booth #BR2 for more information.
Axcella Therapeutics (AXLA) has announced a Phase 2a clinical trial to evaluate AXA1125 as a potential treatment for Long COVID, focusing on fatigue and muscle weakness. Lead by researchers from Oxford University, the trial aims to start by year-end 2021 with top-line data expected by mid-2022. The trial will enroll approximately 40 patients to assess AXA1125's impact on mitochondrial function. This initiative underscores Axcella's commitment to addressing unmet medical needs in a growing patient population.
Axcella Therapeutics, a clinical-stage biotechnology company, will host a virtual R&D Day on October 26, 2021, at 10:00 a.m. ET. The event will unveil the company's upcoming clinical program and discuss ongoing projects for overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH). Key opinion leaders and Axcella's management will present their progress and platform innovations. The name change to Axcella Therapeutics emphasizes its focus on developing therapies for complex diseases. A live audio webcast will be available on their website.
Axcella (NASDAQ: AXLA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The live audio webcast of the presentation is scheduled for 4:30 p.m. ET and can be accessed via the company's website. A replay will be available for 90 days. Axcella is focused on treating complex diseases through its proprietary endogenous metabolic modulator (EMM) compositions. Its lead candidates are in Phase 2/2b development targeting overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH).
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation, focusing on their approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions, will be available via a live audio webcast at 7:00 a.m. ET. A replay will be accessible for 90 days. Axcella's pipeline includes candidates aimed at reducing the risk of overt hepatic encephalopathy recurrence and treating non-alcoholic steatohepatitis.
Axcella (Nasdaq:AXLA) announced the publication of results from its AXA1125-003 clinical study in The American Journal of Gastroenterology. The study demonstrated that AXA1125 and AXA1957 are well-tolerated, with significant reductions in key biomarkers for nonalcoholic fatty liver disease (NAFLD). Notably, 39% of subjects saw a ≥30% reduction in liver fat. Following this, Axcella has initiated the Phase 2b EMMPACT clinical trial of AXA1125 for patients with nonalcoholic steatohepatitis (NASH), aiming to enroll approximately 270 patients.
FAQ
What is the market cap of Axcella Health (AXLA)?
What is Axcella Health Inc. known for?
What is the Axcelerator™ platform?
Which therapeutic areas does Axcella focus on?
How does Axcella’s DAAC therapeutics work?
What recent achievements has Axcella made?
Who are Axcella's key partners?
How does Axcella fund its research initiatives?
What is the significance of DAAC therapeutics?
What makes Axcella’s drug development process unique?
How does Axcella keep its stakeholders informed?
